BioLineRx (BLRX) Common Equity (2012 - 2025)

BioLineRx's Common Equity history runs 14 years deep, the most recent figure standing at $23.3 million for Q4 2025.

• In Q4 2025, Common Equity rose 73.43% year-over-year to $23.3 million; the TTM figure through Dec 2025 stood at $23.3 million (up 73.43% YoY), while the FY2025 annual figure was $23.3 million, up 73.43% from the prior year.
• Common Equity was $23.3 million for Q4 2025 at BioLineRx, up from $19.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $73.9 million in Q2 2021 to a low of $8.5 million in Q3 2024.
• Historically, Common Equity has averaged $36.2 million across 5 years, with a median of $22.2 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Common Equity soared 209.06% in 2021, then plunged 76.35% in 2023.
• A 5-year view of Common Equity shows it stood at $68.1 million in 2021, then retreated by 25.33% to $50.8 million in 2022, then tumbled by 73.99% to $13.2 million in 2023, then gained by 1.8% to $13.5 million in 2024, then jumped by 73.43% to $23.3 million in 2025.
• The last three Common Equity figures came in at $23.3 million (Q4 2025), $19.5 million (Q3 2025), and $20.1 million (Q2 2025), per Business Quant data.